Abstract:Background Abnormal reactivation of androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) mainly results from overexpression and down-regulation of AR. Sumoylation of AR can influence its function. However, regulation of AR sumoylation by SUMO E3 ligases PIASs to modify AR distribution and stability are not well understood. Methods We assessed the potential effect of SUMO3 modification on AR intracellular localization by immunostaining in AR-negative prostate cancer DU145 cells, and detected the effect of PIAS1/SUMO3 overexpression on AR sumoylation related degradation. Then we characterized AR sumoylation sites involved modified by SUMO3, and the key residue of PIAS1 involved in itself sumoylation and further mediated AR sumoylation (sumo3-conjugated), translocation and degradation. Finally we detected the recognition of PIAS1 (sumoylation ligase) to MDM2, a ubiquin ligase mediated AR degradation. Results We demonstrate that SUMO E3 ligase PIAS1, along with SUMO3, mediates AR cytosolic translocation and subsequent degradation via a ubiquitin-proteasome pathway. Although AR sumoylation occurs prior to ubiquitination, the SUMO-acceptor lysine 386 on AR, together with ubiquitin-acceptor lysine 845, contribute to PIAS1/SUMO3-induced AR nuclear export, ubiquitination and subsequent degradation. Moreover, PIAS1 itself is modified by SUMO3 overexpression, and mutation of SUMO-acceptor lysine 117 on PIAS1 can impair AR cytoplasmic distribution, demonstrating the essential role of sumoylated PIAS1 in AR translocation. We further determine that sumoylated PIAS1 interacts with AR lysine 386 and 845 to form a binary complex. Consistent with the effect on AR distribution, SUMO3 modification of PIAS1 is also required for AR ubiquitination and degradation by recruiting ubiquitin E3 ligase MDM2. Conclusion Taken together, SUMO3 modification of PIAS1 modulates AR cellular distribution and stability. Our study provided the evidence the crosstalk between AR sumoylation and ubquitination mediated by PIAS1 and SUMO3.

SUMOylation and SUMO-interacting Motif (SIM) of Metastasis Tumor Antigen 1 (MTA1) Synergistically Regulate Its Transcriptional Repressor Function.

SUMOylation of the M6a-Rna Methyltransferase METTL3 Modulates Its Function.

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome

Metastasis-Associated Protein 1/nucleosome Remodeling and Histone Deacetylase Complex in Cancer

Regulation of Epithelial–Mesenchymal Transition through SUMOylation of Transcription Factors

SUMOylation down-regulates rDNA transcription by repressing expression of upstream-binding factor and proto-oncogene c-Myc

Gene Profiling of MTA1 Identifies Novel Gene Targets and Functions.

E3 Ubiquitin Ligase Cop1 Regulates The Stability And Functions Of Mta1

SUMOylation of GPS2 protein regulates its transcription-suppressing function.

SUMOylation of TARBP2 regulates miRNA/siRNA efficiency

SUMO-2 Promotes Mrna Translation by Enhancing Interaction Between Eif4e and Eif4g.

SUMO protease SENP1 deSUMOylates and stabilizes c-Myc

MTA1 localizes to the mitotic spindle apparatus and interacts with TPR in spindle assembly checkpoint regulation

MAVS deSUMOylation by SENP1 inhibits its aggregation and antagonizes IRF3 activation

SUMO engages multiple corepressors to regulate chromatin structure and transcription

A crucial role of SUMOylation in modulating Sirt6 deacetylation of H3 at lysine 56 and its tumor suppressive activity

A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis.

Mechanism of MTA1 Protein Overexpression-Linked Invasion. MTA1 Regulation of Hyaluronan-Mediated Motility Receptor (HMMR) Expression and Function.

Chromatin Modifier MTA1 Regulates Mitotic Transition and Tumorigenesis by Orchestrating Mitotic Mrna Processing

SUMO3 Modification by PIAS1 Modulates Androgen Receptor Cellular Distribution and Stability